The aim of the present study was to discuss the differences between overall survival (OS) and progression-free survival (PFS) in patients with BRAF V600E-mutated advanced CRC who were treated with chemotherapy alone versus chemotherapy combined with a targeted therapy. This evidence concerns the gene BRAF and colorectal carcinoma.